Money Talks in Hospitals’ Adoption of Oncology Biosimilars
Hospitals’ use of biosimilars for three major oncology drugs increased from 18-37% in 2020 to 84-93% in 2024.…
FDA Approves First Treatment for MAS in Still Disease
The FDA has approved the interferon gamma-blocking antibody emapalumab-lzsg (Gamifant) for the treatment of macrophage activation syndrome (MAS)…
Methotrexate Adds No Benefit to Adalimumab in Psoriasis
TOPLINE: In adults with psoriasis, adding methotrexate to adalimumab did not improve effectiveness or drug survival compared with…
IL-5 Inhibitors May Be Steroid Alternative For Rx of DRESS
TOPLINE: A retrospective case series found that treatment with an interleukin (IL)-5 inhibitor reduced eosinophil levels and improved…